Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02450708 · ClinicalTrials.gov registry record · NA

Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA Genotypes

A NA study of Leukemia, sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
NA
Development phase
511
Enrollment target
10
Study locations

NCT02450708: Active NA study of Leukemia, sponsored by Memorial Sloan Kettering Cancer Center.

NCT02450708 is a NA study of Leukemia that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 511 participants, roughly in line with the 485-participant average among 233 other Leukemia trials with a reported enrollment target. The trial reports 10 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02450708, a NA study of Leukemia, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
511 participants
Enrollment target
10
Study locations

Study Summary

This study tests whether adding certain genetic factors to the process of picking a stem cell donor can decrease the chances that the patient's leukemia will come back after bone marrow transplantation. Stem cell donors are "matched" based on genes called human leukocyte antigens (HLA). Currently, donors are selected largely on the basis of HLA gene typing alone. There is published data to show that donors with specific other genes called killer immunoglobulin-like receptors (KIR) may protect AML patients from having their leukemia return after a transplant. In this study, the best HLA matched donors will be tested for the KIR genes. If there is more than 1 donor available, a recommendation will be provided to study doctors as to which donors have potentially favorable KIR genes. The study doctors may or may not choose to use this donor for transplant or not based on his/her own judgment. Transplant care will not change otherwise as a result of this study. This study is being done to demonstrate that AML patients who have donors with specific KIR and HLA genes will have a better outcome following transplant.

Conditions Studied

Leukemia

Interventions

  • GENETIC KIR genotyping
  • GENETIC HLA genotyping

Study Locations (10)

Texas

  • Baylor University Medical Center - Dallas
  • Md Anderson Cancer Center - Houston

Florida

  • Moffitt Cancer Center - Tampa

Massachusetts

  • Dana Farber Cancer Institute - Boston

Minnesota

  • Mayo Clinic Cancer Center - Rochester

New Jersey

  • Hackensack University Medical Center Cancer Center - Hackensack

New York

  • Memorial Sloan Kettering Cancer Center - New York

North Carolina

  • Duke University Medical Center - Durham

Ohio

  • Ohio State University - Columbus

Trial Details

FieldValue
Enrollment Target 511 participants
Start Date 2015-05
Est. Completion 2026-05
Phase NA

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02450708

The ClinicalTrials.gov registry entry for NCT02450708 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 511 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 485-participant average among 233 other Leukemia trials with a reported enrollment target. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Leukemia appearing as the primary indexed condition, and to 2 interventions - of which KIR genotyping is the first listed.

NCT02450708 reports 10 study locations spanning 9 distinct geographic areas - top geographies include Texas, Florida, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT02450708 about?

NCT02450708 is a clinical study titled "Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA Genotypes". This study tests whether adding certain genetic factors to the process of picking a stem cell donor can decrease the chances that the patient's leukemia will come back after bone marrow transplantation. Stem cell donors are "matched" based on genes called human leukocyte antigens (HLA). Currently, ...

What is the current status of trial NCT02450708?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 511 participants. The study started on 2015-05. Estimated completion is 2026-05.

What conditions does trial NCT02450708 study?

This clinical trial studies the following conditions: Leukemia.

What interventions are being tested in trial NCT02450708?

The interventions under investigation include: KIR genotyping (GENETIC), HLA genotyping (GENETIC).

Who is sponsoring clinical trial NCT02450708?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02450708 being conducted?

This trial has 10 study locations across Florida, Massachusetts, Minnesota, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Leukemia

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.